Current common therapeutic approaches include combinations with drugs that target (a) bypass mechanism, such as MET inhibitors in cells with MET amplification, (b) common cancer pathways, such as apoptosis, cell cycle or MAPK pathways, (c) critical downstream effectors of EGFR, and (d) anti-folate and/or platinum chemotherapy. The gene discussed is EGFR; the disease is cancer.